First in the U.S! Palliative Care VR Educational Material by Jolly Good and Emergency Medicine Specialists

Jolly Good US Inc. (Brookline, Massachusetts, USA CEO: Kensuke Joji), a developer of medical VR, is pleased to announce that it has developed the first “Palliative Care Communication (*1) Training VR” in the United States in collaboration with Brigham and Women’s Hospital, a Harvard affiliated hospital. In addition, using this VR, we will hold a medical VR seminar at “GSA2023”, Gerontological Society of America.

In the U.S., about 90% of terminally ill patients wish to spend their final days at home, but many of them spend those days in the hospital, and one of the major reasons is the lack of communication between doctors, patients, and their families. Therefore, Jolly Good US Inc. decided to jointly develop this product because we believe that training medical professionals on communication in palliative care by using VR, they can efficiently and effectively acquire communication skills.

Dr. Ouchi, an Associate Professor of Emergency Medicine at Harvard Medical School, a joint development partner will be a speaker at the VR seminar to be held at “GSA 2023”, Gerontological Society of America. He will give a lecture on training assessment skills, a basic skill for palliative care by using the jointly developed VR.

Jolly Good US Inc. will continue to verify the effectiveness of this VR, develop medical VR for “Apple Vision Pro (*2)” in various medical fields, and accelerate business development with an eye on the global market.

(*1) Palliative care refers to “improve the quality of life of patients and their families facing challenges associated to life-threatening illnesses, whether physical, psychological, social, or spiritual. The quality of life of caregivers improves as well.” (

(*2) Apple Vision Pro is a mixed reality headset type PC developed by Apple as the first spatial computer. (

Miscommunication Between Medical Professionals and Patients Affects the Type of Care Patients Receive towards the End of Life

In the U.S., about 90% of terminally ill patients wish to spend the last days of their lives at home, but in reality, only about 30% of patients spend their final days at home. This is due to the fact that clinicians, patients, and their families often communicate and make decisions about the future treatment plan and how to meet the end of life for terminally ill patients within a few minutes in the emergency room, where miscommunication is said to occur frequently.

Furthermore, few opportunities exist for clinicians not trained in palliative care to acquire serious illness communication skills due to issues of limited time and cost.

Palliative Care Communication Training VR” Content Overview

In this content, a terminally ill patient is brought to the emergency department (ED) with difficulty breathing and is unable to speak. This scene is recreated in which a doctor communicates with a patient’s family (daughter) and decides together on the most patient-centered treatment for the patient, allowing students to experience the doctor’s perspective.

Overview of Palliative Care VR Seminar

A VR seminar utilizing the newly developed Palliative Care Communication Training VR will be held at “GSA 2023”, Gerontological Society of America meeting to be held in Tampa, Florida.

Date: Friday, November 10, 2023, 12:00-13:30
Venue: Tampa Convention Center, Room 103
Speaker: Dr. Kei Ouchi (Associate Professor of Medicine at Harvard Medical School)

*The first 20 visitors to the venue will be able to experience a demonstration using VR goggles.

Palliative Care VR Booth Overview

Dates: Thursday, November 9Saturday, November 11, 2023
Venue: Tampa Convention Center West Hall
Booth number: 102
Official website of “GSA 2023”

Dr. Kei Ouchi, Associate Professor of Emergency Medicine at Harvard Medical School, Comments

Research has demonstrated that clinicians who are trained in palliative care communication skills can reduce communication errors with patients and their families and provide more patient-centered, end-of-life care. Unfortunately, opportunities to learn this palliative care communication skill are rare for non-palliative care clinicians due to training personnel, time, and cost.

Training in palliative care communication skills using VR would allow wider dissemination nationwide. The VR technology allows learners to repeatedly high-stress, clinical situation from physician’s perspective regardless of location or time. We expect that creating this dissemination strategy for evidence-based, palliative care communication skills will ultimately improve the quality of end-of-life care in the U.S.


Kei Ouchi, MD, MPH is a clinician-scientist and clinically active as an associate physician in the ED and a home hospital physician in the Department of Medicine at Brigham and Women’s Hospital. Dr. Ouchi is an Associate Professor of Emergency Medicine at Harvard Medical School. After growing up in Osaka, Japan, Dr. Ouchi received his MD from Georgetown and MPH from Harvard. Dr. Ouchi’s research focuses on identifying older adults who would benefit from advance care planning conversations and empowering them to formulate their goals for medical care in the ED. Dr. Ouchi is a recipient of numerous awards, including the Paul B. Beeson Emerging Leaders Career Development Award in Aging from the National Institutes on Aging and the Sojourns Scholars Leadership Award from the Cambia Health Foundation. Additionally, he has also served as a medical advisor for Jolly Good Inc. since 2023.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.
The combined expertise of Cordance Medical and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
Medixine prepares for 2024 with two key senior hires, VP of Operations in the U.S. and VP of Engineering in Finland. The appointments will enhance support and service to the company’s U.S.-based partners, including leading respiratory homecare provider Lincare and a major medical device manufacturer. In addition, the new hires will enable streamlined design, testing, and deployment of new product features for more patient-centric, cost and time-effective treatment of chronic conditions.
Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.
Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

By using this website you agree to accept Medical Device News Magazine Privacy Policy